Meeting
2023 ASCO Annual Meeting
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.
Authors
Rui Liu
Singlera Genomics Ltd., Shanghai, China
Rui Liu , De-Zhen Guo , Ao Huang , Cheng-Cheng Ma , Min-Jie Xu , Yi-Ying Liu , Ming-Yang Su , Hua Chen , Yun-Zhi Zhang , Qi-Ye He , Zhi-Xi Su , Xin-Rong Yang , Jia Fan , Jian Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4128)
DOI
10.1200/JCO.2023.41.16_suppl.4128
Abstract #
4128
Poster Bd #
449
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma at early to intermediate stages (BCLC 0 to B).
First Author: Alexandre Prieur
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.
First Author: Jagpreet Chhatwal
Poster
2021 ASCO Annual Meeting
Prognostic value of plasma hPG80 (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.
First Author: Alexandre Prieur
Poster
2020 ASCO Virtual Scientific Program
Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.
First Author: Naga P. Chalasani